Almonertinib plus anlotinib for first-line advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be removed by surgery or treated with radiation and chemotherapy together.
- Your cancer cells have both an EGFR mutation and a TP53 mutation (special gene changes).
- You have not had chemotherapy or radiation for advanced cancer, or if you did, it was more than 6 months ago.
- You are between 18 and 75 years old, and your general health is good enough for daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- Your blood counts and organ function (liver, kidneys) are within acceptable ranges, and you do not have serious heart problems, active infections, or bleeding risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new experimental drug (called TQB2928) combined with a standard targeted therapy pill for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination can help when standard EGFR inhibitors are no longer effective.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
This study tests a new combination of two drugs, almonertinib and SHR-1701, for people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if this combination can help control the cancer and is safe to use.
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.